| Abstract [eng] |
Astaxanthin and Curcumin have a strong antioxidant capacity and exhibit various biological activities, such as anti-cancer potential, anti-inflammatory and antitumor activities, improving immunity. However, due to poor solubility and low bioavailability, their clinical use in drug treatment is limited. To address these limitations, liposomal astaxanthin and curcumin have been offered. Liposomes which are similar in structure to cell membranes and are commonly utilized as drug delivery systems capable of encapsulating hydrophobic bioactive compounds. The aim of this study is develop and characterize a liposomal drug delivery system containing astaxanthin and curcumin. Successful design and optimized formulation of liposomal astaxanthin and curcumin, enhanced drug delivery performance, optimized formulation techniques, and enhanced outcomes in quality and control assessments are expected results of this study. In addition, the assessment of scalability and stability under different conditions of the final formulation is another expected outcome to ensure its possible potential in the pharmaceutical market. According to previous studies, liposomal formulations of curcumin and astaxanthin have been studied individually and single liposomal system has not been explored. By formulating them together despite their different characteristics, and converting the liposome dispersion, this study presents a unique and innovative strategy and offers a novel approach with potential benefits in drug delivery systems. |
